# A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CCX168 in Healthy Participants

> **NCT05984251** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 48 (actual)

## Conditions studied

- Vasculitis
- Systemic Lupus Erythematosus (SLE)

## Interventions

- **DRUG:** CCX168
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05984251
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12-21
- **Primary completion:** 2010-09-19
- **Final completion:** 2011-04-11
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2023-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05984251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05984251, "A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CCX168 in Healthy Participants". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT05984251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*